Citrulline (Amino Acid) : Physiology, Evidence, and Clinical Translation

Citrulline: The Urea Cycle Intermediate and the Vascular-Nitric Oxide Axis

Citrulline is a non-proteinogenic amino acid that occupies a unique intersection in human metabolism. It is not incorporated into proteins during ribosomal translation. It is not a neurotransmitter. It is not a direct antioxidant. Its biological significance derives from its position as a metabolic intermediary, a carrier of nitrogen, and a precursor for the regulated synthesis of arginine and, subsequently, nitric oxide. Citrulline is the molecule that allows the body to bypass the splanchnic sequestration of dietary arginine, to recycle the byproducts of nitric oxide synthesis back into functional substrate, and to detoxify ammonia through its role in the urea cycle. This monograph is written for the reader who seeks to understand why a compound once dismissed as a mere ureotelic intermediate has emerged as a clinically relevant agent for the modulation of vascular function, protein metabolism, and exercise performance. We dissect the compartmentalized biochemistry, grade the evidence by organ system, and map the therapeutic protocols that translate mechanism into clinical application.

---

Part 1. The Compartmentalized Biology of Citrulline: Intestine, Liver, Kidney, and Endothelium

A meaningful discussion of citrulline must begin with the recognition that it is not uniformly distributed throughout the body. It is synthesized in specific tissues, transported in the plasma, and consumed in other tissues. This inter-organ metabolic architecture is the foundation of its physiology and the basis for its therapeutic use.

The Intestinal-Liver Axis: Why Citrulline Bypasses the Arginine Problem

Dietary arginine is subject to extensive first-pass extraction by the intestinal epithelium and the liver. Approximately 40 to 60 percent of ingested arginine is metabolized in the splanchnic bed before reaching the systemic circulation, primarily by the action of arginase, which converts arginine to ornithine and urea. This splanchnic sequestration makes oral arginine an inefficient method for increasing systemic arginine availability. Citrulline solves this problem. It is synthesized in the enterocytes of the small intestine from glutamine, glutamate, and proline, released into the portal circulation, and passes through the liver largely unextracted. The liver expresses the urea cycle enzymes, including argininosuccinate synthetase and argininosuccinate lyase, which convert citrulline to arginine, but under normal conditions, the liver does not consume citrulline at a high rate because the urea cycle is regulated by the availability of ammonia and ornithine, not citrulline. This means that orally administered citrulline escapes splanchnic extraction and reaches the systemic circulation, where it is taken up by the kidneys and, to a lesser extent, by the endothelium and other tissues, for conversion to arginine.

The Renal-Arginine Axis: The Kidney as the Systemic Arginine Factory

The proximal tubules of the kidney are the primary site of citrulline-to-arginine conversion in the body. The kidney expresses high levels of argininosuccinate synthetase and argininosuccinate lyase, the two enzymes required for this conversion. Citrulline, delivered by the renal artery, is combined with aspartate to form argininosuccinate, which is then cleaved to yield arginine and fumarate. The arginine is released into the renal vein and enters the systemic circulation, where it becomes available to all tissues for protein synthesis, nitric oxide production, creatine synthesis, and other arginine-dependent processes. This renal conversion of citrulline to arginine is the basis for citrulline's superiority over arginine as a method for increasing systemic arginine availability. A single oral dose of citrulline produces a larger and more sustained elevation in plasma arginine than an equivalent dose of arginine itself.

The Endothelial Nitric Oxide Synthase Coupling: A Direct Role for Citrulline

The endothelium converts arginine to nitric oxide and citrulline via the enzyme endothelial nitric oxide synthase (eNOS). The citrulline produced in this reaction is not a waste product. It can be recycled back to arginine within the endothelial cell via the citrulline-NO cycle, in which argininosuccinate synthetase and argininosuccinate lyase are co-expressed with eNOS. This recycling pathway provides a local source of arginine that is independent of plasma arginine concentrations, and it may be particularly important under conditions of oxidative stress, when the availability of arginine for eNOS is limiting. This positions citrulline not merely as a precursor for arginine in the kidney, but as a direct participant in the regulation of endothelial NO production at the site of synthesis.

1A. A Clinical Taxonomy of Citrulline Insufficiency

Citrulline is not classified as an essential or conditionally essential amino acid in standard nutritional texts. Yet the functional consequences of a deficit in citrulline flux are well-characterized in specific clinical contexts.

Absolute Supply-Side Insufficiency: The Intestinal Failure Paradigm. The small intestine is the primary site of endogenous citrulline synthesis. In conditions of massive intestinal resection (short bowel syndrome), severe villous atrophy (celiac disease, tropical sprue), or radiation enteritis, the mass of functional enterocytes is reduced, and citrulline synthesis declines. A fasting plasma citrulline concentration below 20 micromoles per liter is a biomarker of severe intestinal dysfunction and is predictive of dependence on parenteral nutrition. This is a true deficiency state with functional consequences: reduced systemic arginine availability, impaired urea cycle function with hyperammonemia, and compromised nitric oxide production. The plasma citrulline level in this context is not merely a biomarker; it is a direct reflection of a loss of metabolic capacity.

Kinetic Insufficiency: When Endogenous Synthesis Is Adequate at Rest but Inadequate Under Demand. The basal rate of citrulline synthesis, approximately 5 to 10 grams per day in a healthy adult, is sufficient to maintain normal plasma arginine and urea cycle function in the unstressed state. However, conditions that increase the demand for arginine, wound healing, sepsis, pregnancy, rapid growth, can exhaust the capacity of the intestinal-renal axis. The clinical phenotype is not a dramatic metabolic crisis but a subtle limitation: impaired wound collagen deposition, reduced endothelial NO-dependent vasodilation, and a reduced capacity to clear ammonia during a protein load. This state of kinetic insufficiency is not detectable by a fasting plasma citrulline level alone; it requires a dynamic assessment of the response to an arginine or protein challenge.

Pathological Demand Surge and the NO-Exhaustion Hypothesis. In conditions characterized by systemic endothelial dysfunction, including atherosclerosis, diabetes mellitus, hypertension, and the metabolic syndrome, the consumption of arginine by eNOS is chronically elevated as the endothelium attempts to compensate for reduced NO bioactivity. Simultaneously, the activity of arginase is often upregulated in these conditions, diverting arginine away from NO synthesis and toward the production of ornithine and proline, which can contribute to vascular fibrosis and remodeling. The combination of increased eNOS demand and increased arginase competition creates a state of relative arginine deficiency within the endothelial cell. This is the NO-exhaustion hypothesis. Exogenous citrulline, by providing a substrate for the citrulline-NO cycle that is not subject to arginase competition, can theoretically restore endothelial NO production without being consumed by arginase. This hypothesis is supported by preclinical data and by early-phase human studies, but it has not been tested in a large, definitive clinical trial with hard cardiovascular endpoints.

1B. Organ System Consequences of Citrulline Depletion

Cardiovascular and Vascular Systems. The endothelium is the organ system most directly affected by citrulline status. A reduction in citrulline availability, whether due to intestinal failure, aging, or metabolic disease, constrains the citrulline-NO cycle and limits the endothelial capacity for NO synthesis. The functional consequence is a progressive impairment of flow-mediated vasodilation, an increase in arterial stiffness, and a pro-thrombotic endothelial phenotype. The epidemiological finding that plasma citrulline concentrations are inversely associated with carotid intima-media thickness and with the presence of coronary artery disease is mechanistically grounded in this loss of endothelial NO reserve. The clinical question is whether citrulline supplementation can reverse established endothelial dysfunction or slow its progression, a question that has been addressed in small trials with positive but not yet definitive results.

Skeletal Muscle: The Protein Synthesis and Detoxification Interface. Skeletal muscle is not a major site of citrulline synthesis or conversion, but it is a target of citrulline's metabolic effects. Citrulline supplementation has been shown in multiple human studies to increase muscle protein synthesis, an effect that is not fully explained by its conversion to arginine. The proposed mechanisms include a direct stimulation of the mTORC1 signaling pathway, an improvement in muscle microvascular blood flow via enhanced NO-mediated vasodilation, and a reduction in the muscle's net release of ammonia during exercise by providing substrate for the urea cycle in the perivenous hepatocytes. The net effect is an improvement in net protein balance, a reduction in post-exercise fatigue, and an acceleration of recovery. These effects have been demonstrated in both young, healthy adults and in older individuals with sarcopenia, though the data in the latter group are less extensive.

Hepatic System: The Urea Cycle and Ammonia Detoxification. Citrulline is an obligate intermediate of the urea cycle. It is synthesized from ornithine and carbamoyl phosphate in the mitochondria of periportal hepatocytes, transported to the cytosol, and condensed with aspartate to form argininosuccinate. A deficiency of citrulline synthesis, as occurs in ornithine transcarbamylase deficiency, results in hyperammonemia, a life-threatening metabolic emergency. Acquired citrulline deficiency, as in short bowel syndrome or severe liver disease, can impair the urea cycle's capacity to clear ammonia, particularly after a protein-rich meal. Supplementation with citrulline, by providing the substrate for the downstream reactions of the urea cycle, can enhance ammonia clearance and reduce postprandial hyperammonemia. This effect has been demonstrated in patients with urea cycle disorders and in patients with cirrhosis.

Renal System: The Arginine Factory and Its Limits. The kidney is the primary site of citrulline-to-arginine conversion. In chronic kidney disease, the renal mass is reduced, and the capacity for this conversion is diminished. The result is a progressive decline in systemic arginine availability, which may contribute to the endothelial dysfunction, the impaired wound healing, and the anemia of chronic kidney disease. Citrulline supplementation in this population is mechanistically attractive, as it provides the substrate that the remaining renal tissue can convert to arginine. However, the safety and efficacy of this approach in advanced chronic kidney disease, where the capacity to handle nitrogenous waste is already compromised, have not been established.

Immunological and Wound Healing Systems. Arginine is essential for the proliferation and function of T-lymphocytes and for the synthesis of collagen by fibroblasts in healing wounds. The immune system's demand for arginine can be substantial during systemic infection or after major trauma. Citrulline, by providing a precursor that bypasses hepatic arginase, can sustain arginine availability for immune function and wound healing even when dietary arginine is limited or when arginase activity is elevated by the inflammatory response. The clinical application of this principle is most advanced in the field of perioperative nutrition, where immunonutrition formulas containing arginine, and by extension citrulline, are used to reduce post-operative infectious complications.

Gastrointestinal System: The Enterocyte as Citrulline Source and Target. The intestinal epithelium synthesizes citrulline and also benefits from its downstream products. Arginine, derived from citrulline, is a precursor for polyamine synthesis via ornithine decarboxylase. Polyamines are essential for enterocyte proliferation and for the maintenance of intestinal barrier integrity. A citrulline deficit, therefore, can impair the regenerative capacity of the intestinal epithelium, creating a vicious cycle in which intestinal damage reduces citrulline synthesis, and reduced citrulline availability impairs intestinal repair. This gut-citrulline-gut axis is a potential therapeutic target in inflammatory bowel disease and in the management of intestinal failure.

Reproductive and Developmental Systems. Pregnancy is a state of increased demand for arginine and nitric oxide. The placental circulation is highly dependent on NO for the maintenance of low vascular resistance. Fetal growth requires a sustained supply of arginine for protein synthesis. Citrulline supplementation during pregnancy has been investigated in animal models of intrauterine growth restriction, with promising results, but human data are extremely limited. The safety of citrulline in human pregnancy has not been established, and it should not be used outside of a clinical trial in this population.

---

Part 2. The Chemistry of Citrulline: Structure, Synthesis, and Metabolic Fate

Citrulline is an alpha-amino acid with the chemical formula C6H13N3O3. Its distinguishing feature is the ureido group (-NH-CO-NH2) on its side chain, which differentiates it from its structural analog arginine, which bears a guanidino group (-NH-C(NH)-NH2). This ureido group is the molecular basis for citrulline's unique metabolic properties. It is the site of aspartate addition in the argininosuccinate synthetase reaction, and it is the product of the nitric oxide synthase reaction.

Endogenous Synthesis: The Intestinal Glutamine-to-Citrulline Pathway

The small intestine synthesizes citrulline from glutamine, the most abundant amino acid in plasma and the primary respiratory fuel of the enterocyte. Glutamine is deamidated to glutamate, which is then transaminated to alpha-ketoglutarate or converted to ornithine via the pyrroline-5-carboxylate pathway. Ornithine, in the presence of carbamoyl phosphate synthesized by carbamoyl phosphate synthetase I, is converted to citrulline by ornithine transcarbamylase in the mitochondria of the enterocyte. This pathway consumes two molecules of ATP and requires N-acetylglutamate as an allosteric activator of carbamoyl phosphate synthetase. The citrulline synthesized in the enterocyte is released into the portal circulation, completing the intestinal phase of the inter-organ citrulline-arginine axis.

Metabolic Fate: Conversion to Arginine and Recycling Via the Urea Cycle

The citrulline that reaches the systemic circulation has three primary fates. The quantitatively dominant fate is renal conversion to arginine, as described above. The second fate is direct incorporation into the urea cycle in the liver, where it accepts aspartate to form argininosuccinate and subsequently arginine and fumarate. The third fate is participation in the endothelial citrulline-NO cycle, where it is converted to arginine locally for eNOS-dependent NO synthesis. The fumarate produced in the argininosuccinate lyase reaction enters the tricarboxylic acid cycle, linking citrulline metabolism to energy production. The aspartate required for the argininosuccinate synthetase reaction is derived from the transamination of oxaloacetate, linking citrulline metabolism to the malate-aspartate shuttle and to gluconeogenesis.

---

Part 3. Citrulline and the Nitric Oxide Synthase Family: Substrate, Product, and Regulator

The relationship between citrulline and the three isoforms of nitric oxide synthase is fundamental to its biology.

Endothelial NOS (eNOS): The Vascular Citrulline-NO Cycle

eNOS is the enzyme responsible for the basal production of NO that maintains vascular tone and endothelial health. It converts arginine to NO and citrulline in a reaction that requires oxygen, NADPH, tetrahydrobiopterin (BH4), flavin adenine dinucleotide (FAD), and flavin mononucleotide (FMN). The citrulline produced can be recycled to arginine within the endothelial cell via argininosuccinate synthetase and argininosuccinate lyase. This recycling pathway is functionally coupled to eNOS; the enzymes are co-localized in caveolae, and the arginine produced is channeled directly to eNOS. The citrulline-NO cycle is therefore a mechanism for maintaining NO production when extracellular arginine is limited or when arginase competes for the available arginine. Exogenous citrulline can enter this cycle, providing a source of arginine that is not accessible to arginase.

Neuronal NOS (nNOS): The Neurotransmission Interface

nNOS is expressed in specific populations of neurons in the central and peripheral nervous systems, where NO functions as a retrograde neurotransmitter involved in synaptic plasticity, learning, and memory. The citrulline-NO cycle is also present in neurons that express nNOS, though its quantitative significance is less well-characterized than in the endothelium. The potential for citrulline to modulate neuronal NO production has implications for conditions ranging from migraine to neurodegeneration, but the clinical data are essentially absent.

Inducible NOS (iNOS): The Double-Edged Sword

iNOS is expressed in macrophages, microglia, and other cell types in response to inflammatory stimuli. It produces large quantities of NO that contribute to the killing of intracellular pathogens but can also cause tissue damage through the formation of peroxynitrite. The relationship between citrulline and iNOS is complex. Providing citrulline as a substrate for iNOS could, in theory, enhance the antimicrobial NO burst. However, in conditions of chronic inflammation, iNOS can become uncoupled and produce superoxide instead of NO, contributing to oxidative stress. The net effect of citrulline supplementation in states of iNOS activation is not predictable from first principles and has not been adequately studied in humans.

---

Part 4. The Evidence Mapped by Quality and Mechanism

The clinical evidence for citrulline is more robust than for many nutraceuticals, with multiple randomized controlled trials in specific indications. The quality of the evidence varies by organ system and clinical endpoint.

4.1. Citrulline as an Arginine Prodrug: The Pharmacokinetic Advantage

The most fundamental and well-replicated finding in the citrulline literature is that oral citrulline is superior to oral arginine for increasing plasma arginine concentrations. A systematic review of pharmacokinetic studies found that an oral dose of citrulline produces a larger area under the curve for plasma arginine than an equimolar dose of arginine. The mechanism is the splanchnic bypass described in Part 1. This pharmacokinetic advantage is the basis for all downstream therapeutic applications. A typical oral dose of 3 to 6 grams of L-citrulline increases plasma arginine by 200 to 400 percent within one to two hours, with the elevation sustained for four to six hours. This compares favorably to the smaller and shorter-lived increase produced by oral arginine, which is also more likely to cause gastrointestinal side effects including nausea, cramping, and diarrhea.

4.2. Vascular Function and Blood Pressure: The Endothelial Evidence

Multiple randomized controlled trials have investigated the effect of citrulline supplementation on endothelial function and blood pressure. A meta-analysis of these trials concluded that citrulline supplementation, at doses of 3 to 6 grams per day for one to eight weeks, significantly reduces systolic and diastolic blood pressure, with a weighted mean reduction of approximately 4 to 6 mmHg for systolic pressure. The effect is most pronounced in individuals with pre-existing hypertension or prehypertension, consistent with the model that citrulline restores a deficient endothelial NO production rather than driving NO synthesis above physiological levels in healthy individuals. The mechanism is supported by studies showing that citrulline improves flow-mediated dilation, reduces arterial stiffness as measured by pulse wave velocity, and increases markers of NO bioavailability such as plasma nitrite and nitrate. The effect on hard cardiovascular endpoints, myocardial infarction, stroke, cardiovascular mortality, has not been assessed in a long-term randomized trial, and current evidence supports citrulline as an adjunctive therapy for blood pressure reduction, not as a replacement for established antihypertensive medications.

4.3. Exercise Performance and Recovery: The Muscle Metabolism Evidence

Citrulline malate, a salt of citrulline with malic acid, has been extensively studied as an ergogenic aid. The malate component is included for its theoretical role in the tricarboxylic acid cycle and the malate-aspartate shuttle, though the evidence that malate contributes independently to the ergogenic effect is weak. The combination has been studied more extensively than citrulline alone in the exercise context.

A meta-analysis of randomized controlled trials concluded that citrulline malate supplementation, typically at a dose of 6 to 8 grams administered 60 minutes before exercise, significantly reduces the rating of perceived exertion during high-intensity exercise and reduces post-exercise muscle soreness at 24 and 48 hours. The effect on maximal strength and power output is small and inconsistent. The effect on endurance performance is suggestive but not definitively established. The mechanisms proposed include enhanced ammonia clearance via the urea cycle, improved muscle oxygenation via NO-mediated vasodilation, and a direct enhancement of mitochondrial oxidative phosphorylation. The reduction in post-exercise soreness is a clinically meaningful outcome for athletes in training and for individuals beginning an exercise program.

The acute dosing protocol for performance is 6 to 8 grams of citrulline malate, providing approximately 3 to 4 grams of citrulline, taken 45 to 60 minutes before exercise. Chronic dosing at 3 to 6 grams per day for one to two weeks has been shown to improve time to exhaustion and reduce subjective fatigue, but the evidence for chronic protocols is less robust than for acute pre-exercise dosing.

4.4. Erectile Function: The Penile NO Connection

Erectile function is dependent on NO-mediated vasodilation of the penile cavernosal arteries, and the penile endothelium expresses the complete citrulline-NO cycle. The hypothesis that citrulline supplementation can improve erectile function is mechanistically sound and supported by a single, small randomized controlled trial. In this study, men with mild erectile dysfunction who received 1.5 grams of L-citrulline daily for one month reported a significant improvement in erection hardness and satisfaction compared to placebo. The effect size was modest but statistically significant, and the dose was lower than that used in most vascular studies. This finding has not been replicated in a large, multi-center trial, and citrulline is not a first-line therapy for erectile dysfunction. It may have a role as an adjunct for men with mild, primarily vasculogenic erectile dysfunction, particularly those who cannot tolerate or prefer to avoid phosphodiesterase-5 inhibitors. A reasonable evidence-based protocol is 1.5 to 3 grams of L-citrulline per day in divided doses, with the expectation that the effect, if it occurs, will develop over several weeks of continued use.

4.5. Sickle Cell Disease: The Rheological Frontier

A novel application of citrulline is in the management of sickle cell disease. The pathophysiology of vaso-occlusive crisis involves endothelial dysfunction, NO depletion, and the adhesion of sickled erythrocytes to the endothelium. Citrulline, by providing substrate for endothelial NO synthesis, could theoretically improve microvascular blood flow and reduce the frequency or severity of vaso-occlusive episodes. A small pilot study in children with sickle cell disease demonstrated that citrulline supplementation at 0.1 grams per kg per day improved symptoms and reduced the frequency of pain crises. A subsequent, larger trial did not confirm a significant reduction in the primary endpoint, though some secondary endpoints were positive. The data are inconclusive, and the use of citrulline in sickle cell disease should be considered investigational pending larger, definitive trials.

4.6. Intestinal Failure and Short Bowel Syndrome: The Biomarker and Therapeutic

Plasma citrulline is a well-validated biomarker of functional enterocyte mass and is used clinically to assess the severity of intestinal failure and to predict the potential for weaning from parenteral nutrition. A plasma citrulline concentration below 20 micromoles per liter in a patient with short bowel syndrome indicates severe intestinal insufficiency and a low probability of achieving independence from parenteral nutrition. The therapeutic use of citrulline in this population, beyond its role as a biomarker, is logical but not extensively studied. By providing substrate for arginine synthesis, citrulline supplementation could improve protein synthesis, wound healing, and immune function in patients with intestinal failure. Small clinical studies have shown that citrulline supplementation in short bowel syndrome increases plasma arginine and improves nitrogen balance, but the effect on clinical outcomes such as infectious complications, wound healing, and parenteral nutrition dependence has not been evaluated in randomized trials.

---

Part 5. A Clinical Dosing Compendium: Protocols and Theoretical Frameworks

The dosing of citrulline is determined by the target tissue, the desired pharmacokinetic profile, and the clinical context. The protocols below are stratified by the strength of the underlying evidence.

5.1. Evidence-Based Protocols: Dosing with Published Human Data

Vascular Function and Blood Pressure Reduction. The goal is a sustained elevation of plasma arginine to support endothelial NO synthesis. The evidence-based protocol is 3 to 6 grams of L-citrulline per day, divided into two doses, for a minimum of four to eight weeks. The division of the daily dose is recommended because the half-life of the resulting plasma arginine elevation is approximately four to six hours, and a twice-daily schedule provides more consistent substrate availability to the endothelium. The blood pressure effect is modest, a reduction of 4 to 6 mmHg systolic, and should be monitored. Citrulline is not a replacement for guideline-directed antihypertensive therapy but can be considered an adjunct in patients with prehypertension or stage 1 hypertension who are motivated to use a nutritional intervention. The combination of citrulline with established endothelial-protective nutrients such as omega-3 fatty acids, coenzyme Q10, and dietary nitrate is mechanistically coherent but has not been tested in factorial trials.

Acute Exercise Performance Enhancement. The goal is a pre-exercise elevation of plasma arginine to improve muscle blood flow, ammonia clearance, and the perception of effort. The evidence-based protocol is a single dose of 6 to 8 grams of citrulline malate (providing 3 to 4 grams of L-citrulline), dissolved in water, taken on an empty stomach 45 to 60 minutes before exercise. The empty-stomach recommendation is to avoid competition with other amino acids for intestinal transport and to ensure rapid absorption. The effect on performance is an improvement in the subjective experience of high-intensity exercise, a reduction in the rating of perceived exertion, and a reduction in post-exercise muscle soreness, rather than a direct increase in maximal power or strength. This protocol is most appropriate for athletes in sports involving repeated high-intensity efforts, resistance training with high volume, and individuals who experience significant post-exercise soreness that limits training frequency.

Erectile Function Support. The goal is to support the penile endothelial citrulline-NO cycle. The evidence, limited to a single positive trial, supports a dose of 1.5 to 3 grams of L-citrulline per day, divided into two doses. The onset of effect, if it occurs, is gradual over several weeks, consistent with the time required for sustained endothelial substrate provision to improve NO-dependent vasodilation. This protocol is most appropriate for men with mild vasculogenic erectile dysfunction who wish to trial a nutritional intervention before or alongside lifestyle modifications such as weight loss and exercise. It is not appropriate for men with severe erectile dysfunction, those with erectile dysfunction of primarily psychological or neurogenic origin, or those with unstable cardiovascular disease.

5.2. Theoretical and Postulated Dosing Frameworks for Future Investigation

Perioperative and Critical Care Nutrition. Rationale: major surgery and critical illness impose an immense demand on arginine-dependent pathways, including immune function, wound healing, and endothelial NO production. Standard immunonutrition formulas contain arginine, but the splanchnic extraction problem limits its systemic availability. Citrulline, by bypassing splanchnic extraction, could be a more effective method for delivering arginine in the perioperative period. Postulate: a pre-operative loading protocol of 6 grams of L-citrulline per day for five days before major abdominal surgery, followed by continued supplementation at the same dose during the post-operative period, with primary endpoints of wound healing (collagen deposition in wound drains), infectious complications, and length of hospital stay. This protocol requires safety monitoring for hemodynamic effects, as the combination of citrulline-induced vasodilation and perioperative fluid shifts could produce hypotension.

Sarcopenia and Age-Related Muscle Loss. Rationale: citrulline stimulates muscle protein synthesis through mTORC1 activation and improves muscle microvascular blood flow. Aging is associated with anabolic resistance, a reduced muscle protein synthetic response to dietary protein and exercise. Postulate: a chronic supplementation protocol of 3 to 5 grams of L-citrulline twice daily, in combination with a protein-rich meal and a resistance exercise program, in adults aged 65 and older with sarcopenia. The primary endpoint would be the change in lean body mass by dual-energy X-ray absorptiometry and the change in muscle strength and physical function over six months. The hypothesis is that citrulline will augment the anabolic response to exercise and nutrition, resulting in greater gains in muscle mass and function than exercise and nutrition alone.

Ammonia Detoxification in Cirrhosis. Rationale: the cirrhotic liver has a reduced capacity for urea synthesis, and patients with cirrhosis are at risk for hyperammonemia, particularly after a protein load or a gastrointestinal bleed. Citrulline, by providing substrate for the urea cycle downstream of the defective mitochondrial steps, could enhance ammonia clearance. Postulate: a trial of L-citrulline at 6 grams per day in patients with compensated cirrhosis and a history of minimal hepatic encephalopathy, with primary endpoints of fasting and post-prandial plasma ammonia and psychometric tests of cognitive function. The safety concern is that the conversion of citrulline to arginine could theoretically increase NO production and worsen the hyperdynamic circulatory state of cirrhosis, though this has not been observed in the limited studies to date.

Sickle Cell Disease: A Definitive Pediatric Trial. Rationale: the preliminary data are promising but inconclusive. A large, multi-center, randomized, placebo-controlled trial of L-citrulline in children with sickle cell disease, with a dose of 0.1 to 0.2 grams per kg per day and a duration of 12 months, is required to determine whether citrulline reduces the frequency of vaso-occlusive crises, the rate of hospitalization, or the need for opioid analgesia. The primary endpoint should be the annualized rate of vaso-occlusive crises requiring medical attention. Secondary endpoints should include markers of endothelial function, hemolysis, and quality of life.

Pregnancy-Induced Hypertension and Preeclampsia Prevention. Rationale: preeclampsia is a disorder of placental endothelial dysfunction and systemic NO depletion. The placental circulation is highly dependent on NO for the maintenance of low vascular resistance. Citrulline, by providing substrate for placental eNOS, could theoretically improve uteroplacental blood flow and reduce the risk of preeclampsia in high-risk pregnancies. Postulate: a randomized trial of L-citrulline at 3 to 5 grams per day, initiated in the early second trimester, in women with a history of preeclampsia or other high-risk features. The primary endpoint would be the incidence of preeclampsia. The safety of this intervention in pregnancy must be established before such a trial can proceed, as the effects of sustained NO augmentation on fetal development are not fully characterized.

5.3. Universal Principles Governing Citrulline Dosing

Citrulline Is Superior to Arginine for Systemic Effects. The pharmacokinetic advantage of citrulline, its ability to bypass splanchnic extraction and produce a sustained elevation of plasma arginine, makes it the preferred agent for any therapeutic application that requires increased systemic arginine availability. Oral arginine retains a role for local effects in the gastrointestinal tract, but for vascular, muscular, and systemic applications, citrulline is the superior choice.

The Malate Moiety Is Not Essential for Vascular or Metabolic Effects. Citrulline malate is the form most commonly used in exercise studies, but the malate component has not been shown to contribute independently to the ergogenic effect. For vascular, metabolic, and anti-aging applications, pure L-citrulline is appropriate and eliminates the unnecessary malate load. The dose should be calculated based on the citrulline content: citrulline malate is typically a 2:1 ratio of citrulline to malate, so 6 grams of citrulline malate provides approximately 4 grams of citrulline.

Tolerance and Gastrointestinal Effects. Citrulline is well-tolerated at doses up to 15 grams per day in clinical studies. Gastrointestinal side effects, including bloating, cramping, and loose stools, can occur at doses above 10 grams per day but are uncommon at the 3 to 6 gram doses used in most clinical protocols. Citrulline does not produce the nausea and cramping that are frequently reported with high-dose oral arginine. The malate component in citrulline malate can be mildly laxative in sensitive individuals at doses above 8 grams.

Timing of Dosing Depends on the Target Effect. For acute pre-exercise performance, a single dose 45 to 60 minutes before the activity is appropriate. For sustained vascular and metabolic effects, divided twice-daily dosing is recommended to maintain plasma arginine elevation throughout the day. For wound healing and perioperative applications, continuous provision through the pre-operative and post-operative period is the logical strategy.

Monitoring of Blood Pressure Is Prudent. Citrulline's blood pressure-lowering effect is modest but real. In hypertensive patients on pharmacotherapy, the addition of citrulline could theoretically produce additive hypotension, though this has not been reported as a significant clinical problem in the existing trials. Blood pressure should be monitored when initiating citrulline, particularly in patients on multiple antihypertensive agents.

---

Part 6. The Unresolved Frontier

Three questions define the boundary of current citrulline science.

Does Long-Term Citrulline Supplementation Reduce Cardiovascular Events? The blood pressure-lowering and endothelial function data are consistent and mechanistically coherent. The missing piece is a large, long-term, randomized trial with hard clinical endpoints. Such a trial would require thousands of patients followed for five to ten years, at a cost that makes it unlikely to be conducted without public-sector funding. The question may instead be answered by Mendelian randomization studies using genetic variants that influence plasma citrulline levels, or by large observational cohorts with repeated measures of citrulline intake and cardiovascular outcomes. Until such data are available, citrulline should be positioned as an adjunct to, not a replacement for, established cardiovascular risk reduction strategies.

What Is the Mechanism of Citrulline's Effect on Muscle Protein Synthesis? The observation that citrulline stimulates muscle protein synthesis is robust, but the mechanism is incompletely understood. The conversion to arginine and subsequent NO-mediated vasodilation explains only part of the effect. There is evidence for a direct effect of citrulline on the mTORC1 pathway that is independent of arginine and NO, but the molecular target of citrulline in the muscle cell has not been identified. Resolving this mechanism could lead to the development of more potent citrulline analogs for the treatment of sarcopenia and other muscle wasting conditions.

Can Citrulline Serve as a Therapeutic Agent in Urea Cycle Disorders Beyond Ornithine Transcarbamylase Deficiency? Citrulline is an established therapy for ornithine transcarbamylase deficiency, where it provides substrate for the urea cycle downstream of the genetic block. The role of citrulline in other urea cycle disorders, and in acquired urea cycle dysfunction due to liver disease or drug toxicity, is less well-defined. The potential for citrulline to enhance ammonia clearance in acute liver failure, in valproate-induced hyperammonemia, and in the post-prandial hyperammonemia of cirrhosis is a promising but underexplored area of clinical research.

---

Part 7. Synthesis for an Evidence-Based Approach

Citrulline is a molecule whose clinical utility derives directly from the compartmentalized architecture of human amino acid metabolism. It is the solution to a problem that evolution did not anticipate: that oral arginine, the direct precursor of nitric oxide, would be so extensively extracted by the splanchnic bed that its systemic availability would be limited. By synthesizing citrulline in the intestine, releasing it into a portal circulation that spares it from hepatic extraction, and converting it to arginine in the kidney and the endothelium, the body has created a metabolic bypass that allows for the regulated delivery of arginine to the tissues that require it.

The therapeutic exploitation of this bypass is supported by a growing body of clinical evidence. The most robust data are in the domains of vascular function and exercise performance, where citrulline supplementation at doses of 3 to 8 grams per day produces measurable improvements in blood pressure, endothelial function, exercise tolerance, and post-exercise recovery. The evidence in erectile function, sickle cell disease, and intestinal failure is suggestive but requires replication in larger trials. The evidence for a direct anabolic effect on skeletal muscle is mechanistically intriguing and clinically important for the aging population, but the human data are still preliminary.

The clinical dosing compendium presented here reflects this state of the evidence. The protocols for blood pressure reduction, exercise performance, and erectile function are supported by published human trials and can be applied with reasonable confidence. The protocols for perioperative nutrition, sarcopenia, cirrhosis, and pregnancy are theoretical frameworks that require validation in randomized trials before they can be recommended for routine clinical use.

Citrulline's position at the intersection of the urea cycle, the citrulline-NO cycle, and the inter-organ trafficking of amino acids makes it a uniquely versatile molecule. It is simultaneously a detoxification agent, a vasodilator precursor, and an anabolic stimulus. Its clinical future will be determined by the rigor with which these distinct functions are tested in the populations that stand to benefit from them: the hypertensive patient with endothelial dysfunction, the athlete seeking to train harder and recover faster, the elderly individual fighting the progressive loss of muscle and vascular health, and the patient with liver disease struggling to clear the ammonia that threatens brain function. The science of citrulline is a reminder that the most clinically useful molecules are often those that the body itself uses to solve its own metabolic problems.